Tissue Genesis Inc. will receive $1.1 million for the rights to license its regenerative cell technology to a Mainland company for use in treating pelvic health disorders.

Under the agreement, American Medical Systems has a four year option to obtain exclusive distribution and license rights to Tissue Genesis’ regenerative cell technology, including the Tissue Genesis Cell Isolation System, with an additional two year right of first refusal, according to a news release from the two companies.
The Tissue Genesis Cell Isolation System processes a small amount of the patient’s own adipose tissue into a concentration of millions of regenerative cells, including adult stem cells, microvascular endothelial cells, and other cells. Those cells can be coated onto artificial implants or directly injected into damaged tissue, to improve circulation and support the formation of new tissue.
“AMS is committed to being at the forefront of innovation to improve the lives of the millions of people worldwide who suffer from pelvic health disorders,” said Tony Bihl, President and CEO of American Medical Systems. “We are delighted to partner with Tissue Genesis, a leader in the burgeoning field of regenerative cell technology, to research therapies that may fundamentally improve patient treatment within our markets.”